The SEC claimed that Dewitz used several trading accounts, including those in his wife’s name, to make the purchases, which took place as the merger talks advanced. Following the announcement of the merger, Cleveland BioLabs’ stock price surged by 46%, resulting in Dewitz’s alleged illegal gains.
Dewitz’s legal team has yet to respond to requests for comment, while the SEC declined to provide further details beyond its public filings.
